This was not an attempt to do anything to the share price, up or down. It was to prepare the way for more capital to fund trials. Since these trials are necessary and add value, new shares to fund them would only be dilutive in a relative sense: it would be better off for us if the trials were financed by cash from a debt issuance or partnership deal. It appears neither is on the immediate horizon. Then again, Erhlic might get a phone call tomorrow or next week... you just don't know. But you don't do a shelf registration when capital is being thrown at you.
Market Data 
Markets 
AI
